查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018782

藥物和基因遞送裝置市場：按技術、裝置類型、分子類型、最終用戶、應用和治療領域分類——2026-2032年全球市場預測

Drug & Gene Delivery Devices Market by Technology, Device Type, Molecule Type, End User, Application, Therapeutic Area - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，藥物和基因輸送設備市場價值將達到 53.2 億美元，到 2026 年將成長至 59.2 億美元，到 2032 年將達到 110.6 億美元，複合年成長率為 11.01%。

主要市場統計數據
基準年 2025 53.2億美元
預計年份：2026年 59.2億美元
預測年份 2032 110.6億美元
複合年成長率 (%) 11.01%

對藥物和基因輸送設備的市場趨勢進行策略分析，重點在於材料創新、數位系統、監管變化和患者需求。

現代藥物和基因遞送裝置的發展趨勢體現在材料創新、數位技術應用以及對患者治療效果的持續關注等方面的融合。生物材料的最新進展，結合微型電子元件和嵌入式感測器，為精準給藥、封閉回路型遞送和遠端監測創造了新的機會。同時，監管預期和報銷框架也在不斷發展，以適應複雜的產品和數位化治療方法，這要求裝置開發人員從早期階段就將臨床、技術和商業性因素整合起來。

材料突破、數位工具、製造創新和監管趨勢推動藥物和基因輸送裝置發生變革性變化。

變革性的變化正在重塑藥物和基因遞送裝置的競爭格局和技術格局。材料科學的突破，例如先進水凝膠、脂質奈米顆粒系統和多功能聚合物，正在催生新的製劑和控釋方案。同時，數位化工具和嵌入式感測器正在將裝置從被動載體轉變為智慧平台，為臨床醫生和保險公司提供給藥方案的洞察、用藥依從性反饋以及真實世界數據流。

評估 2025 年美國關稅對供應鏈、零件採購、定價策略和製造業韌性的累積影響。

美國將於2025年宣布並實施關稅，將對製藥和基因遞送設備生態系統產生多方面的影響。關稅將改變零件採購的經濟格局，推高某些進口材料和子組件的價格，並促使企業採用替代籌資策略。這種轉變將迫使製造商和設備開發商加快對其供應商組合的重新評估，探索近岸採購方案，並對二級供應商進行認證，以降低單一來源風險。

透過細分洞察技術選擇、設備類型、分子類別、最終用戶、應用和治療重點如何影響設計和採用。

系統性的細分方法揭示了不同技術平台、裝置形態、分子類別、臨床應用、應用標靶和治療優先順序的設計選擇和商業化路徑的差異。在技​​術層面，我們將重點放在基於水凝膠、脂質體、奈米顆粒和聚合物的平台。每種平台在釋放動力學、穩定性以及對高敏感性生技藥品和基因療法的適用性方面都存在不同的考量。這些材料的選擇直接決定了裝置的結構、滅菌策略和低溫運輸要求。

美洲、歐洲、中東和非洲以及亞太地區的採用、法規環境、製造能力和商業化的區域趨勢。

區域趨勢對產品上市時機、監管方式、生產策略及商業化路徑均有顯著影響。在美洲，市場高度重視快速商業化、大規模臨床檢驗以及支持器材驅動治療方法的整合式醫療路徑，市場參與企業通常優先考慮可擴展的生產能力和完善的上市後監測。而在歐洲、中東和非洲，監管差異和國家醫保體系導致採購環境分散，需要製定個人化的打入市場策略、提供在地化的臨床證據，並與當地經銷商建立合作關係才能有效應對市場挑戰。

從企業層面深入了解策略聯盟、技術組合、製造投資、監管定位和競爭優勢。

企業層面的策略日益著重於將專有技術與策略夥伴關係關係結合的生態系統策略。產業領導企業正有選擇地投資於可適應多種醫療設備類型和治療領域的平台技術，同時與契約製造製造商、配方專家和數位醫療供應商建立合作夥伴關係。這些合作縮短了複雜複合產品的上市時間，並將技術風險分散到更廣泛的合作夥伴網路。

為行業領導者提供實用建議，以優先考慮技術、改進設備設計、加強供應鏈和改進患者照護策略。

產業領導者應採取果斷行動，將洞察轉化為競爭優勢。優先投資於可應用於多個治療領域且與高度敏感的生技藥品和基因載體相容的平台技術，並分配研發資源以整合能夠顯著改善用藥依從性和臨床療效的數位化能力。透過確保關鍵零件的多元化供應來源並實施近岸或雙源策略，加強與供應商的關係，降低全球關稅和物流中斷帶來的風險。

本文檔概述了調查方法，包括資料來源、一級和二級調查程序、檢驗方案以及應用於醫療設備評估的分析架構。

本調查方法整合了第一手訪談、針對性技術檢驗和二手資料研究，以建立可靠的證據基礎。第一手訪談包括對企業高管、研發負責人、監管專家、生產合作夥伴和臨床醫生進行結構化訪談，以了解實際應用中的限制、推動技術應用普及的因素以及尚未滿足的需求。二手資料研究包括同行評審文獻、監管指導文件、專利申請和企業資訊披露，以全面檢驗技術能力和過往案例。

摘要強調，需要將策略重點、技術趨勢、法規環境和設備設計與患者和市場實際情況相協調。

結論整合了材料平台、器材模式、供應鏈現狀和區域趨勢等領域所辨識出的策略挑戰。它強調，整合思維對於製藥和基因遞送器材領域的成功至關重要；也就是說，技術差異化必須與生產規模化、監管前瞻性和商業化準備相結合。在產品生命週期早期就協調這些要素的相關人員，將更有利於簡化核准流程、確保有利的採購管道，並向臨床醫生和支付方展示產品的實際價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 藥物與基因遞送裝置市場：依技術分類

  • 水凝膠型
  • 脂質體
  • 奈米顆粒
  • 聚合物基

第9章 藥物與基因遞送裝置市場：依裝置類型分類

  • 自動注射器
  • 點滴幫浦
  • 無針注射器
  • 筆式注射器
  • 注射器

第10章：藥物與基因遞送裝置市場：依分子類型分類

  • 生物製藥
    • 單株抗體
    • 胜肽
    • 重組蛋白
  • 基因治療
    • 非病毒
      • 基於脂質的
      • 聚合物基
    • 病毒載體
      • 腺病毒
      • 慢病毒
      • 逆轉錄病毒
  • 低分子

第11章 藥物與基因遞送裝置市場：依最終使用者分類

  • 診所
  • 居家醫療
  • 醫院
  • 研究所

第12章 藥物與基因遞送裝置市場：依應用領域分類

  • 控釋
  • 智慧配送
  • 緩釋
  • 精準投放

第13章 藥物與基因傳遞裝置市場：依治療領域分類

  • 循環系統
  • 糖尿病
  • 感染疾病
  • 腫瘤學

第14章 藥物與基因遞送設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 藥物與基因遞送設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 藥物與基因遞送設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國藥物與基因遞送設備市場

第18章：中國藥物與基因遞送設備市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • AstraZeneca plc
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Bayer AG
  • Becton, Dickinson & Company
  • Catalent, Inc.
  • Epeius Biotechnologies Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Gerresheimer AG
  • Johnson & Johnson Services, Inc.
  • Lonza Group AG
  • Medtronic plc
  • Nipro Corporation
  • Novartis AG
  • Sartorius AG
  • Shanghai Sunway Biotech Co., Ltd.
  • SHL Medical AG
  • SiBiono GeneTech Co., Ltd.
  • Stevanato Group SpA
  • Terumo Corporation
  • UniQure NV
  • West Pharmaceutical Services, Inc.
  • Ypsomed Holding AG
Product Code: MRR-A86604082727

The Drug & Gene Delivery Devices Market was valued at USD 5.32 billion in 2025 and is projected to grow to USD 5.92 billion in 2026, with a CAGR of 11.01%, reaching USD 11.06 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.32 billion
Estimated Year [2026] USD 5.92 billion
Forecast Year [2032] USD 11.06 billion
CAGR (%) 11.01%

Strategic introduction to the drug and gene delivery device landscape highlighting materials innovation, digital systems, regulatory change, and patient needs

The modern drug and gene delivery device landscape is defined by a convergence of materials innovation, digital enablement, and a relentless focus on patient outcomes. Recent advances in biomaterials, coupled with miniaturized electronics and embedded sensors, have created new opportunities for precision dosing, closed-loop delivery, and remote monitoring. At the same time, regulatory expectations and reimbursement frameworks are evolving to account for combination products and digitally augmented therapeutics, requiring device developers to integrate clinical, technical, and commercial considerations from the outset.

This introduction frames the interplay between scientific innovation and practical deployment. It highlights how cross-disciplinary teams-bringing together polymer scientists, formulation experts, mechanical and software engineers, and clinical stakeholders-are now required to develop differentiated delivery solutions. The narrative also recognizes the growing role of patient experience as a design driver: ease of use, safety, and adherence now directly influence adoption. Finally, the section sets a foundation for the deeper analyses that follow, establishing the critical dependencies that will determine which technologies and business models succeed in the coming years.

Transformative shifts reshaping drug and gene delivery devices through materials breakthroughs, digital tools, manufacturing innovation, and regulatory dynamics

Transformative shifts are reshaping the competitive and technical landscape for drug and gene delivery devices. Materials science breakthroughs such as advanced hydrogels, lipid nanoparticle systems, and multifunctional polymers are enabling new formulations and controlled-release profiles. Concurrently, digital tools and embedded sensors are transitioning devices from passive carriers to intelligent platforms that provide dosing intelligence, adherence feedback, and real-world data streams for clinicians and payers.

Manufacturing innovation is another vector of change: modular, scalable production approaches and investments in onshore capabilities are reducing lead times and improving quality control for complex delivery systems. Regulatory expectations are moving in parallel, with authorities placing greater emphasis on integrated risk management, cybersecurity for connected devices, and lifecycle data. Taken together, these shifts favor organizations that combine deep materials expertise with systems engineering, robust clinical evidence generation, and nimble regulatory strategies. The result is a landscape where multidisciplinary integration, rather than single-technology advantage, determines sustainable differentiation.

Assessing cumulative effects of United States tariffs for 2025 on supply chains, component sourcing, pricing strategies, and manufacturing resilience

The announcement and implementation of United States tariffs for 2025 introduces a multi-dimensional effect on the drug and gene delivery device ecosystem. Tariffs alter the economics of component sourcing, making some imported materials and subassemblies more expensive and incentivizing alternative sourcing strategies. This change forces manufacturers and device developers to re-evaluate supplier portfolios, consider nearer-shore options, and accelerate qualification of secondary suppliers to mitigate single-source risk.

Beyond immediate cost implications, tariffs can influence strategic decisions about where to locate manufacturing and final assembly. Firms with flexible, modular manufacturing architectures are better positioned to shift production footprints and absorb input-cost variability. Procurement teams will need to rework total-cost-of-ownership models to incorporate tariff impacts, logistics volatility, and longer lead times. Importantly, regulatory submissions and supplier change controls must be anticipated as part of these sourcing shifts. The net effect is a renewed emphasis on supply chain resilience and localized capability development as core strategic priorities for device makers and their partners.

Segmentation insights on how technology selection, device types, molecule classes, end users, applications, and therapeutic focus shape design and adoption

A disciplined segmentation approach reveals where design choices and commercialization pathways diverge across technology platforms, device formats, molecular classes, care settings, application goals, and therapeutic priorities. Based on Technology, studies focus on Hydrogel Based, Liposomal, Nanoparticle, and Polymer Based platforms, each offering distinct release kinetics, stability profiles, and compatibility considerations for sensitive biologics and gene therapies. These material choices directly shape device architecture, sterility strategies, and cold-chain requirements.

Based on Device Type, analysis spans Auto Injector, Infusion Pump, Needle Free Injector, Pen Injector, and Syringe formats; device ergonomics, actuation mechanisms, and safety interlocks vary significantly across these forms and create different barriers to entry. Based on Molecule Type, the landscape distinguishes Biologic, Gene Therapy, and Small Molecule programs. The Biologic category further breaks into Monoclonal Antibody, Peptide, and Recombinant Protein, each with unique handling and delivery constraints. The Gene Therapy segment is split between Non Viral and Viral Vector approaches, where Non Viral divides into Lipid Based and Polymer Based carriers and Viral Vector workstreams include Adenoviral, Lentiviral, and Retroviral vectors-factors that influence manufacturing complexity, regulatory pathways, and cold-chain logistics.

Based on End User, insights cover Clinics, Home Healthcare, Hospitals, and Research Laboratories, highlighting different training, support, and device maintenance requirements. Based on Application, analysis evaluates Controlled Release, Smart Delivery, Sustained Release, and Targeted Delivery objectives and how they map to therapeutic intent. Based on Therapeutic Area, the review emphasizes Cardiovascular, Diabetes, Infectious Diseases, and Oncology, each bringing distinct clinical endpoints, dosing windows, and payer dynamics that shape product design and evidence strategies. Together, these segmentation dimensions create an analytical scaffolding for prioritizing investments and tailoring commercialization approaches to specific clinical and market realities.

Regional view of adoption, regulatory climate, manufacturing capabilities, and commercialization across Americas, Europe, Middle East & Africa, Asia-Pacific

Regional dynamics exert a profound influence on adoption timing, regulatory approach, manufacturing strategy, and commercialization pathway. In the Americas, there is a strong emphasis on rapid commercialization, large-scale clinical validation, and integrated care pathways that support device-enabled therapeutics; market entrants often prioritize scalable manufacturing and robust post-market surveillance. In Europe, Middle East & Africa, regulatory heterogeneity and national reimbursement systems require tailored market access strategies, localized clinical evidence, and partnerships with regional distributors to navigate fragmented procurement environments.

In Asia-Pacific, growth is frequently driven by a mix of local innovation hubs, cost-sensitive manufacturing, and rapidly expanding home-health adoption, all of which favor cost-effective, user-friendly devices that can be deployed at scale. Across these regions, differences in supply chain resilience, talent availability, and standards for clinical data shape where companies choose to invest in production capacity, R&D, and commercial teams. Companies that align regulatory strategy, manufacturing footprint, and commercialization priorities with these regional nuances can accelerate market entry and reduce unforeseen compliance or logistics risks.

Company-level insights on strategic alliances, technology portfolios, manufacturing investments, regulatory positioning, and competitive differentiation

Company-level strategies are increasingly centered on ecosystem plays that combine proprietary technologies with strategic partnerships. Leaders invest selectively in platform technologies that can be adapted across multiple device types and therapeutic areas, while also building alliances with contract manufacturers, formulation specialists, and digital health vendors. These collaborations reduce time-to-market for complex combination products and distribute technical risk across a broader partner network.

Investment decisions hinge on demonstrable differentiation: robust IP in delivery mechanisms, validated compatibility with high-value molecules such as monoclonal antibodies or viral vectors, and a credible path to regulatory approval. Firms that disclose clear manufacturing roadmaps, including plans for scale-up and quality systems alignment, tend to attract more favorable partnerships and procurement opportunities. Equally important is a company's ability to generate clinician and patient-centric evidence demonstrating improved adherence, reduced complications, or streamlined care pathways. This evidence underpins discussions with payers and health systems and becomes a decisive factor in adoption and reimbursement conversations.

Practical recommendations for industry leaders to prioritize technologies, refine device design, fortify supply chains, and elevate patient care strategies

Industry leaders should take decisive actions to convert insight into competitive advantage. Prioritize investments in platform technologies that demonstrate cross-therapeutic applicability and compatibility with sensitive biologics and gene vectors, and allocate R&D resources to integrate digital functions that measurably improve adherence and clinical outcomes. Strengthen supplier relationships by qualifying multiple sources for critical components and by developing nearer-shore or dual-source strategies to reduce exposure to global tariff and logistics disruptions.

Refine device design by centering human factors and real-world use cases early in development to ensure high usability across Clinics, Home Healthcare, and Hospitals. Align regulatory strategy with evidence-generation plans that can support combination product submissions and address cybersecurity expectations for connected devices. Finally, embed commercialization thinking into product development so that clinical evidence, pricing models, and distribution approaches evolve in parallel with technical milestones; this reduces go-to-market friction and accelerates payer and provider conversations.

Research methodology outlining data sources, primary and secondary research steps, validation protocols, and analytical frameworks applied to device assessment

The research methodology integrates primary interviews, targeted technical validation, and secondary research to build a robust evidence base. Primary research includes structured interviews with executives, R&D leaders, regulatory specialists, manufacturing partners, and clinicians to capture real-world constraints, adoption drivers, and unmet needs. Secondary research encompasses peer-reviewed literature, regulatory guidance documents, patent filings, and corporate disclosures to triangulate technical capabilities and historical precedent.

Validation protocols involve cross-checking interview findings against public filings and regulatory submissions, while analytical frameworks combine technology readiness assessments, supply chain risk scoring, and adoption-mapping exercises. Data synthesis emphasizes reproducibility and auditability: assumptions are documented, sensitivity analyses are conducted where appropriate, and methodological limitations are clearly stated. This layered approach ensures that conclusions rest on multiple evidence streams and that recommendations are actionable for R&D, regulatory, and commercial stakeholders.

Concluding synthesis highlighting strategic priorities, technology trends, regulatory context, and the need to align device design with patient and market realities

The conclusion synthesizes the strategic imperatives uncovered across materials platforms, device modalities, supply chain realities, and regional dynamics. It emphasizes that success in the drug and gene delivery device space requires integrated thinking: technical differentiation must be coupled with manufacturing scalability, regulatory foresight, and commercialization readiness. Stakeholders that coordinate these elements early in the product lifecycle are better positioned to navigate approval pathways, secure favorable procurement, and demonstrate real-world value to clinicians and payers.

Looking ahead, the most sustainable advantages will accrue to organizations that can combine platform extensibility with evidence-generation frameworks that speak to both clinical outcomes and total cost of care. Companies should view device development not as a one-off engineering challenge but as an end-to-end program that links scientific innovation to patient experience and market access. This alignment is the core determinant of long-term adoption and commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug & Gene Delivery Devices Market, by Technology

  • 8.1. Hydrogel Based
  • 8.2. Liposomal
  • 8.3. Nanoparticle
  • 8.4. Polymer Based

9. Drug & Gene Delivery Devices Market, by Device Type

  • 9.1. Auto Injector
  • 9.2. Infusion Pump
  • 9.3. Needle Free Injector
  • 9.4. Pen Injector
  • 9.5. Syringe

10. Drug & Gene Delivery Devices Market, by Molecule Type

  • 10.1. Biologic
    • 10.1.1. Monoclonal Antibody
    • 10.1.2. Peptide
    • 10.1.3. Recombinant Protein
  • 10.2. Gene Therapy
    • 10.2.1. Non Viral
      • 10.2.1.1. Lipid Based
      • 10.2.1.2. Polymer Based
    • 10.2.2. Viral Vector
      • 10.2.2.1. Adenoviral
      • 10.2.2.2. Lentiviral
      • 10.2.2.3. Retroviral
  • 10.3. Small Molecule

11. Drug & Gene Delivery Devices Market, by End User

  • 11.1. Clinics
  • 11.2. Home Healthcare
  • 11.3. Hospitals
  • 11.4. Research Laboratories

12. Drug & Gene Delivery Devices Market, by Application

  • 12.1. Controlled Release
  • 12.2. Smart Delivery
  • 12.3. Sustained Release
  • 12.4. Targeted Delivery

13. Drug & Gene Delivery Devices Market, by Therapeutic Area

  • 13.1. Cardiovascular
  • 13.2. Diabetes
  • 13.3. Infectious Diseases
  • 13.4. Oncology

14. Drug & Gene Delivery Devices Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Drug & Gene Delivery Devices Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Drug & Gene Delivery Devices Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Drug & Gene Delivery Devices Market

18. China Drug & Gene Delivery Devices Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Amgen Inc.
  • 19.6. AstraZeneca plc
  • 19.7. B. Braun Melsungen AG
  • 19.8. Baxter International Inc.
  • 19.9. Bayer AG
  • 19.10. Becton, Dickinson & Company
  • 19.11. Catalent, Inc.
  • 19.12. Epeius Biotechnologies Corporation
  • 19.13. F. Hoffmann-La Roche Ltd.
  • 19.14. Fresenius Kabi AG
  • 19.15. Gerresheimer AG
  • 19.16. Johnson & Johnson Services, Inc.
  • 19.17. Lonza Group AG
  • 19.18. Medtronic plc
  • 19.19. Nipro Corporation
  • 19.20. Novartis AG
  • 19.21. Sartorius AG
  • 19.22. Shanghai Sunway Biotech Co., Ltd.
  • 19.23. SHL Medical AG
  • 19.24. SiBiono GeneTech Co., Ltd.
  • 19.25. Stevanato Group S.p.A.
  • 19.26. Terumo Corporation
  • 19.27. UniQure N.V.
  • 19.28. West Pharmaceutical Services, Inc.
  • 19.29. Ypsomed Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HYDROGEL BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HYDROGEL BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HYDROGEL BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPOSOMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPOSOMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPOSOMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NANOPARTICLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NANOPARTICLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NANOPARTICLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY AUTO INJECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY AUTO INJECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY AUTO INJECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NEEDLE FREE INJECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NEEDLE FREE INJECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NEEDLE FREE INJECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RECOMBINANT PROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RECOMBINANT PROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPID BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPID BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LIPID BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY POLYMER BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ADENOVIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LENTIVIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LENTIVIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY LENTIVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RETROVIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RETROVIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMART DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMART DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SMART DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUSTAINED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUSTAINED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TARGETED DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TARGETED DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TARGETED DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 215. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 220. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 222. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 223. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 248. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 253. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 255. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 256. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 259. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 264. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 265. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 266. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 267. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)